Login / Signup

Mutation screening of germline TP53 mutations in high-risk Chinese breast cancer patients.

Ava KwongVivian Yvonne ShinCecilia Y S HoChun Hang AuThomas P SlavinJeffrey N WeitzelTsun-Leung ChanEdmond S K Ma
Published in: BMC cancer (2020)
In view of the high lifetime risk of malignancy, identification of patients with germline TP53 mutations are important for clinicians to aid in accurate risk assessment and offer surveillance for patients and their families.
Keyphrases
  • risk assessment
  • end stage renal disease
  • ejection fraction
  • dna repair
  • newly diagnosed
  • public health
  • palliative care
  • prognostic factors
  • high resolution
  • patient reported outcomes
  • dna damage
  • human health